News

Olympia Pharmaceuticals | 503B Outsourcer | 503A Compounding Pharmacy

Market 50/100How we got 50/100Source tierUnclassified sourceTier ceiling50/100Independent sourcesnot recordedPublished score50/100Scored at the ceiling for a unclassified source source — it cannot go higher. The number is the source page’s own score, hard-capped at the tier ceiling; corroboration is recorded but cannot lift a score past that cap. Under 40 a claim goes to review instead of publication. Full methodology →
July 28, 2026↗ source

Olympia Pharmaceuticals, operating as both a 503B FDA-registered outsourcing facility and an affiliated 503A compounding pharmacy, has expanded its product directory to include a wide array of injectable peptides and wellness compounds. The company highlights its ability to provide these medications, including popular weight management and longevity agents, to physicians for office use and directly to patients via prescription. This expansion reflects the growing compounding industry response to high demand and shortages of branded peptide drugs.

Related peptides

BPC-157SemaglutideTB-500IpamorelinCJC-1295TirzepatideSermorelinGLP-1 receptor agonistsGLP-1C-peptideLongevityPeptide TBPC-157 / TB-500 BlendCJC 1295 + IpamorelinGLP-1 receptor agonistTB-500 + CJC-1295Peptide therapeuticsTherapeutic peptidesGLP-1R
We summarize, we don't invent — every detail here traces to a real, linked source, and the badge reflects how trustworthy that source is. Read the original and decide for yourself.